Moderna Stock Sees Significant Comeback with 125% YTD Surge
Moderna Stock Sees Significant Comeback with 125% YTD Surge
Published on
Moderna stock (MRNA) has demonstrated a remarkable comeback in 2026, with its value increasing by 125.51% year-to-date. This substantial growth is primarily driven by an FDA approval for a flu vaccine, a strategic corporate pivot, and a robust, expanding product pipeline.
Moderna stock is up 125.51% in 2026, driven by an FDA flu vaccine win, a corporate pivot, and an expanding pipeline. Here's what's moving MRNA.